Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).
Publication
, Conference
Armstrong, AJ; Tombal, B; Sternberg, CN; Higano, CS; Rathkopf, DE; Loriot, Y; Saad, F; Joshua, AM; De Bono, JS; Venner, PM; Carles, J ...
Published in: Journal of Clinical Oncology
May 20, 2014
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2014
Volume
32
Issue
15_suppl
Start / End Page
5007 / 5007
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Armstrong, A. J., Tombal, B., Sternberg, C. N., Higano, C. S., Rathkopf, D. E., Loriot, Y., … Beer, T. M. (2014). Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC). In Journal of Clinical Oncology (Vol. 32, pp. 5007–5007). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2014.32.15_suppl.5007
Armstrong, Andrew J., Bertrand Tombal, Cora N. Sternberg, Celestia S. Higano, Dana E. Rathkopf, Yohann Loriot, Fred Saad, et al. “Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 32:5007–5007. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.5007.
Armstrong AJ, Tombal B, Sternberg CN, Higano CS, Rathkopf DE, Loriot Y, et al. Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 5007–5007.
Armstrong, Andrew J., et al. “Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).” Journal of Clinical Oncology, vol. 32, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2014, pp. 5007–5007. Crossref, doi:10.1200/jco.2014.32.15_suppl.5007.
Armstrong AJ, Tombal B, Sternberg CN, Higano CS, Rathkopf DE, Loriot Y, Saad F, Joshua AM, De Bono JS, Venner PM, Carles J, Mainwaring PN, Evans CP, Noonberg SB, Mansbach HH, Bhattacharya S, Perabo F, Phung D, Beer TM. Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 5007–5007.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2014
Volume
32
Issue
15_suppl
Start / End Page
5007 / 5007
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences